Replies to post #208681 on Biotech Values

[DewDiligence]

AMGN 4Q16 items...

PR:
http://finance.yahoo.com/news/amgen-reports-fourth-quarter-full-212000236.html

CC slides:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjU4MjIwfENoaWxkSUQ9MzY0NTA4fFR5cGU9MQ==&t=1

[mcbio]

AMGN—Repatha shows statsig reduction in CV risk (and non-inferior cognitive function relative to placebo)

Do you view this news as positive for ESPR? Assuming it's at least an incremental positive for ultimate outcome of ESPR's P3 CVOT though I think you separately expressed concerns about enrollment for that trial. (BTW ESPR shares are up almost 20% today at time of this post.)